TABLE 4

Variables predicting survival in patients with interstitial pneumonia with autoimmune features

Characteristic	Unadjusted^#		Adjusted^#
Characteristic	HR (95% CI)	p-value	HR (95% CI)	p-value
Age	1.06 (1.03–1.08)	<0.001	1.05 (1.02–1.08)	0.001
Male sex	1.54 (0.91–2.60)	0.11	1.65 (0.92–2.97)	0.09
Hypothyroidism	1.97 (1.05–3.67)	0.03	1.08 (0.52–2.22)	0.84
Ever smoker	0.92 (0.54–1.54)	0.74	1.11 (0.60–2.05)	0.74
GER therapy	1.12 (0.66–1.88)	0.67	1.38 (0.79–2.43)	0.26
Chronic systemic corticosteroid therapy	0.82 (0.49–1.38)	0.46	1.39 (0.73–2.63)	0.32
Immunosuppressive therapy^¶	0.74 (0.47–1.17)	0.2	0.7 (0.35–1.4)	0.31
UIP pattern⁺	2.4 (1.21–4.76)	0.01	1.72 (0.83–3.56)	0.14
FVC % predicted	0.99 (0.98–1.01)	0.22	1 (0.97–1.02)	0.76
D_LCO % predicted	0.97 (0.96–0.99)	<0.001	0.97 (0.95–0.99)	0.01
Clinical domain	0.56 (0.32–0.96)	0.03
Raynaud's phenomenon	0.57 (0.29–1.10)	0.09
Serologic domain	1.89 (0.59–6.06)	0.28
ANA seropositivity	0.91 (0.51–1.62)	0.75
Morphological domain	1.31 (0.56–3.06)	0.53
HRCT features	0.58 (0.34–1.0)	0.05
SLB features	0.36 (0.11–1.18)	0.09
Multicompartment features	2.01 (1.19–3.38)	0.009

HR: hazard ratio; GER: gastroesophageal reflux; UIP: usual interstitial pneumonia; FVC: forced vital capacity; D_LCO: diffusion capacity of the lung for carbon monoxide; ANA: antinuclear antibody; HRCT: high-resolution computed tomography; SLB: surgical lung biopsy. ^#: N=143; ^¶: azathioprine n=41, mycophenolate mofetil n=19, tacrolimus n=4, and cyclophosphamide n=2; ⁺: based on HRCT or SLB, with SLB serving as final diagnosis when discordant.